Study of Infigratinib in Children With Achondroplasia
Completed · Phase 2
Conditions studied: Achondroplasia
In brief
This is a Phase 2, multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, and efficacy of infigratinib, a fibroblast growth factor receptor (FGFR) 1-3-selective tyrosine kinase inhibitor, in children 3 to 11 years of age with Achondroplasia (ACH) who previously participated in the PROPEL study (Protocol QBGJ398-001) for at least 6 months. The study includes dose escalation with extended treatment, and dose expansion. The study also includes a PK Substudy to fully characterize the pharmacokinetics of infigratinib in children with ACH.
Key facts
- Study ID
- NCT04265651
- Run by
- QED Therapeutics, a BridgeBio company
- People needed
- 84
- Starts
- 2020-03-10
- Expected to finish
- 2024-10-21
- Last updated by the study team
- 2025-10-22
Who can join
Age: 3 and older, up to 11. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Signed informed consent by participant or parent(s) or legally authorized representative (LAR) and signed informed assent by the participant (when applicable).
- Diagnosis of ACH, documented clinically and confirmed by genetic testing.
- At least a 6-month period of growth assessment in the PROPEL study (Protocol QBGJ398-001) before study entry.
- Ambulatory and able to stand without assistance
- Able to swallow oral medication.
You may not qualify if…
- Hypochondroplasia or short stature condition other than ACH.
- In females, having had their menarche.
- Height < -2 or > +2 standard deviations for age and sex based on reference tables on growth in children with ACH.
- Significant concurrent disease or condition that, in the view of the Investigator and/or Sponsor, would confound assessment of efficacy or safety of infigratinib.
- Current evidence of corneal or retinal disorder/keratopathy.
- History of malignancy.
- Currently receiving treatment with agents that are known strong inducers or inhibitors of CYP3A4 and medications which increase serum phosphorus and/or calcium concentration.
- Treatment with growth hormone, insulin-like growth factor 1 (IGF-1), or anabolic steroids in the previous 6 months or long-term treatment (>3 months) at any time.
- Treatment with a C-type natriuretic peptide (CNP) analog, fibroblast growth factor (FGF) ligand trap, or treatment targeting FGFR inhibition at any time.
- Regular long-term treatment (>3 weeks) with oral corticosteroids (low-dose ongoing inhaled steroid for asthma is acceptable).
- Treatment with any other investigational product or investigational medical device for the treatment of ACH or short stature.
- Previous limb-lengthening surgery or guided growth surgery.
- Fracture within 12 months of screening.
Where it is running
- UCSF Benioff Children's Hospital — Oakland, California, United States
- Nemours Alfred I. Dupont Hospital for Children — Wilmington, Delaware, United States
- Johns Hopkins School of Medicine — Baltimore, Maryland, United States
- Cincinnati Children's Hospital Medical Center — Cincinnati, Ohio, United States
- Vanderbilt University Medical Center — Nashville, Tennessee, United States
- Murdoch Children's Hospital — Parkville, Victoria, Australia
- Stollery Children's Hospital — Edmonton, Alberta, Canada
- Hopital Femme Mere Enfant — Lyon, France
- Hopital Necker-Enfants Malades — Paris, France
- Hopital des Enfants — Toulouse, France
- Hospital Universitario La Paz — Madrid, Spain
- Hospital Universitario Virgen de la Victoria — Málaga, Spain
- Vithas Hospital San José — Vitoria-Gasteiz, Álava, Spain
- Sheffield Children's Hospital — Sheffield, England, United Kingdom
- Birmingham Children's Hospital — Birmingham, United Kingdom
- University Hospitals Bristol and Weston NHS Foundation Trust — Bristol, United Kingdom
- Queen Elizabeth University Hospital — Glasgow, United Kingdom
- Evelina London Children's Hospital — London, United Kingdom
- Manchester University Children's Hospital — Manchester, United Kingdom
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.